• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Korean Journal of Physiology & Pharmacology >Synergistic Efficacy of Concurrent Treatment with Cilostazol and Probucol on the Suppression of Reactive Oxygen Species and Inflammatory Markers in Cultured Human Coronary Artery Endothelial Cells
【24h】

Synergistic Efficacy of Concurrent Treatment with Cilostazol and Probucol on the Suppression of Reactive Oxygen Species and Inflammatory Markers in Cultured Human Coronary Artery Endothelial Cells

机译：西洛他唑和普罗布考同时治疗对培养的人冠状动脉内皮细胞中活性氧和炎性标志物的协同增效作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the present study, we aimed to identify the synergistic effects of concurrent treatment of low concentrations of cilostazol and probucol to inhibit the oxidative stress with suppression of inflammatory markers in the cultured human coronary artery endothelial cells (HCAECs). Combination of cilostazol (0.3~3 μM) with probucol (0.03~0.3 μM) significantly suppressed TNF-α-stimulated NAD(P)H-dependent superoxide, lipopolysaccharide (LPS)-induced intracellular reactive oxygen species (ROS) production and TNF-α release in comparison with probucol or cilostazol alone. The combination of cilostazol (0.3~3 μM) with probucol (0.1~0.3 μM) inhibited the expression of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1) more significantly than did the monotherapy with either probucol or cilostazol. In line with these results, combination therapy significantly suppressed monocyte adhesion to endothelial cells. Taken together, it is suggested that the synergistic effectiveness of the combination therapy with cilostazol and probucol may provide a beneficial therapeutic window in preventing atherosclerosis and protecting from cerebral ischemic injury.
机译：在本研究中，我们旨在确定低浓度西洛他唑和普罗布考的同时治疗对人的冠状动脉内皮细胞（HCAECs）中炎症标记的抑制作用，从而抑制氧化应激的协同作用。西洛他唑（0.3〜3μM）与普罗布考（0.03〜0.3μM）的组合可显着抑制TNF-α刺激的NAD（P）H依赖性超氧化物，脂多糖（LPS）诱导的细胞内活性氧（ROS）的产生和TNF-α与单独的普罗布考或西洛他唑相比，α释放。西洛他唑（0.3〜3μM）与普罗布考（0.1〜0.3μM）的组合比单药治疗更显着抑制血管细胞粘附分子1（VCAM-1）和单核细胞趋化蛋白1（MCP-1）的表达。与普罗布考或西洛他唑。与这些结果一致，联合疗法显着抑制了单核细胞粘附于内皮细胞。两者合计，建议西洛他唑和普罗布考联合治疗的协同效力可能为预防动脉粥样硬化和防止脑缺血性损伤提供有益的治疗窗口。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号